Caelum Biosciences to be acquired by division of AstraZeneca in $150M deal By: Philadelphia Business Journal via Business Journals September 30, 2021 at 14:52 PM EDT The deal's value could grow by up to another $350 million if a series of product development milestones are met. Read More >>